IELSG50

IELSG50Pembrolizumab and radiotherapy for previously untreated patients with limited-stage NK/T cell lymphoma who are not eligible for chemotherapy
Participants required:30
Investigator responsible(s):S. Luminari and W. Zhao
Objective(s):The primary objective of the IELSG50 trial is to test the efficacy of concurrent RT- Pembrolizumab in patients with limited-stage high-risk NK/T cell lymphoma who are not eligible or refuse to receive chemotherapy.

Home | Go to Studies

Top